X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/yingli-pharma-presents-a-pivotal-phase-2-study-data-evaluating-linperlisib-in-relapsed-or-refractory-peripheral-t-cell-lymphoma-in-an-oral-session-at-the-american-society-of-hematology-2023-annual-meeting-302010879.html
https://www.prnewswire.com/news-releases/yingli-pharma-announces-first-patient-dosed-in-phase-2-trial-of-linperlisib-for-peripheral-t-cell-lymphoma-301617369.html
https://www.globenewswire.com/news-release/2022/01/20/2370411/0/en/Yingli-Pharma-and-MD-Anderson-Initiate-Strategic-Collaboration-to-Advance-Development-of-Multiple-Oncology-Programs.html
https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html
https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html
https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html
https://www.prnewswire.com/news-releases/yingli-pharma-announces-a-presentation-on-the-phase-2-clinical-trial-of-linperlisib-a-pi3k-selective-inhibitor-in-relapsed-or-refractory-follicular-lymphoma-at-the-european-hematology-association-2021-congress-301310715.html
https://en.prnasia.com/releases/global/yingli-pharma-announce-promising-topline-results-of-a-phase-ii-registration-study-for-treatment-of-relapsed-refractory-follicular-lymphoma-with-the-once-daily-oral-pi3k-inhibitor-linperlisib-313716.shtml
https://en.prnasia.com/releases/global/yingli-pharma-announce-promising-topline-results-of-a-phase-ii-registration-study-for-treatment-of-relapsed-refractory-follicular-lymphoma-with-the-once-daily-oral-pi3k-inhibitor-linperlisib-313716.shtml
https://www.prnewswire.com/news-releases/yingli-pharma-announce-promising-topline-results-of-a-phase-ii-registration-study-for-treatment-of-relapsedrefractory-follicular-lymphoma-with-the-once-daily-oral-pi3k-inhibitor-linperlisib-301260322.html
Market Place
Share 
